Phaseline

Targets › MMP9

MMP9 (Matrix metalloproteinase-9): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 1; Immunology, Other, Neurology; next expected readout Dec 2027.

Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption (By similarity). (UniProt, P14780)

Open in Phaseline: the race on MMP9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Southern CaliforniaMinocycline
Bacterial 70S ribosome inhibitor
MMP9Phase 2Aneurysm, RupturedDec 2027
AshibioAndecaliximab
Matrix metalloproteinase 9 inhibitor
MMP9Phase 2Fibrodysplasia Ossificans Progressiva; Heterotopic Ossification (HO)Dec 2028

Conditions

Fibrodysplasia Ossificans Progressiva (1) Heterotopic Ossification (HO) (1) Aneurysm, Ruptured (1)

Modalities

antibody (1), small molecule (1)

Companies

Ashibio (1) University of Southern California (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.